ChargePoint Technology invests in production capabilities for large-scale containment valves
The new 5-axis machine will speed up the production and delivery of larger diameter valves up to 350 mm.
Powder containment and aseptic transfer valve specialist ChargePoint Technology has invested in new manufacturing machinery at its UK facility to meet increased demand for larger diameter valves for use in large-scale drug manufacturing that requires containment.
The new 5-axis machine is the first of its kind in the UK and forms part of a wider £1 million investment into advanced manufacturing capabilities at the company’s facility in Liverpool. It will enable ChargePoint Technology to speed up the production and delivery of larger diameter valves up to 350 mm (14”).
The investment has been made in response to growing containment demands that are being driven by growth within therapeutic areas, including oncology and hormonal drug products. This is leading to increased volumes of high potency active pharmaceutical ingredients (HPAPIs) being used in the production of tablets, capsules and other solid dosage forms.
Tony O’Sullivan, chief commercial officer at ChargePoint Technology, commented: “We are seeing an increase in demand from solid dose manufacturing companies, including big pharma firms and CMOs in the US and Europe, for large-scale containment valve solutions.
“Our new machinery enables us to manufacture larger diameter valves, directly addressing this market need. In addition, our in-house manufacturing strategy provides us with absolute control over the quality of the final product so our customers can rest assured that they receive high-performing and reliable technology.
“Growth in the high-volume manufacture of generics, particularly in Asia, is also driving demand for larger containment valves, as there is a need to upgrade existing process equipment to safely replicate the production of higher potency off patent drugs, while ensuring drug quality and operator safety. We expect this segment to grow in the future as the pharmaceutical landscape evolves.”
As part of the investment, a new automated washing plant will be used to ensure effective and repeat cleaning of parts with higher throughput capacity, while a new 3-axis coordinate measuring machine (CMM) will also allow for high precision measurement and scanning of critical valve components in-house.
ChargePoint Technology intends to invest further in manufacturing capabilities at its facility over the next 3 years. In particular, it plans to continue to evolve its product design using the latest manufacturing methods to provide further advancements in valve technology.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.